Member Info for shareguard

Well we are a third of the way through Q1 and they have said phase 1 in Q1, we know the vaccine works dont need to be Sherlock Holmes for that because they re-checking that it works with different strains hence SN15 so yea just need delivery method to be finalised they have a license for one but prefer a better one if they can get it right.

We now have a new prefix iSCIB Scancell pipeline sounding likes something rolling off the production line at Fords Dagenham plant, AvidiMab could become the prefix in the vaccine world like Cosworth or Lotus did for Ford a bit of extra vroom for your product.

Recent studies have demonstrated that Scancell's AvidiMab™ technology can be applied to an ImmunoBody® to increase the potency of the T cell response; this modification can be used for the development of any ImmunoBody® cancer vaccine and has also been incorporated into the design of our COVID-19 vaccine programme. Furthermore, this modification has the added advantage of extending the patent life of this platform and any resulting products. Future ImmunoBody® programmes incorporating this modification to enhance the immune response will be identified by the prefix iSCIB

AvidiMab...

AvidiMab™ has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer. A patent application has been filed that seeks broad protection for the AvidiMab™ technology establishing it as Scancell's third proprietary immunotherapy platform technology, together with ImmunoBody® and Moditope®.

The benefits of AvidiMab look strong .

I am just looking through this Doc.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/951851/uk-clean-spc-covid-19-vaccine-astrazeneca-reg174.pdf
This paragraph....
4.8 Undesirable effects
Summary of the safety profile
The overall safety of COVID-19 Vaccine AstraZeneca is based on an interim analysis of pooled data
from four clinical trials conducted in the United Kingdom, Brazil, and South Africa. At the time of
analysis, 23,745 participants =18 years old had been randomised and received either COVID-19
Vaccine AstraZeneca or control. Out of these, 12,021 received at least one dose of COVID-19 Vaccine
AstraZeneca. The median duration of follow-up in the COVID-19 Vaccine AstraZeneca group was
105 days post-dose 1, and 62 days post-dose 2.
AZN conducted 4 trials in 3 countries UK, Brazil and south Africa the 3 countries with deadlier strains i am no scientist but can a virus modify itself to evade a vaccine maybe something not being told here.

s2020 -- whats interesting about the qualcomm deal no mention of any license deal, a partnership so no $$ can be levied what i read is that the partners have shared interest in combining the best of each others contribution and will reap full reward too what % they share in any agreed deal to each individual motor company or their oems could be staggering.

Hi chester/all looking at the delivery system i have taken a small holding in N4p and during research have come across this in a research note covering N4p quite a long read but two parts i have copied and pasted.

https://www.n4pharma.com/wp-content/uploads/2020/11/2020_SP_Angel_N4P_Initiation_Note_FINAL.pdf

From bottom of page 5

Ichor Medical Systems (Private) is developing the UNITE platform,
an automated device for electroporation-mediated nucleic acid administration in
humans. Ichor has struck agreements with Scancell (SCLP.L) and Immunomic
Therapeutics (Private) to support the delivery of DNA vaccine candidates for COVID-19
developed by its partners.

Bottom of Page 15
There are a number of developers with nucleic acid-based vaccine candidates which are
at the preclinical stage of development. Once the Nuvec® COVID-19 programme
completes, the platform may be of interest to these parties to potentially enhance the
activity and delivery of their vaccine. There are currently 14 DNA vaccine candidates at
the preclinical stage. Scancell (SCLP.L) is developing a DNA vaccine which relies on the
SARS-CoV-2 nucleocapsid (N) and S protein antigen to generate an immune response.
Scancell looks to progress to Phase 1 trials in Q121. Cambridge-based DIOSynVax
(private) recently received a £1.9m grant from the UK government to progress its DNA
vaccine candidate, DIOS-CoVax2, into clinical trials (expected by early 2021). Similalry to
Inovio, delivery of DIOS-CoVax2 also relies on a jet injection device (the PharmaJet
Tropis Needle-Free Injector).
Note out of 14 DNA vaccines they highlight only two of them and they have synergies with Scancell John Chiplin being chairman of both and working in the same ball park.
Mentioned them before but no one else seems to think they are in the running but seems to be a little smoke coming out of their camp.
So we have Ichor and Notts uni developing one and maybe N4p come from behind to steal the show just something to look at would not surprise me anyway.
N4p is an interesting company and valued at only 10 million if their delivery system is a success particular the oral one then you could be well in profit.
Best regards

That news is nearly 5 years old so meaningless for today unless you mean in the context they dont always get it right.

Hydrogen fuelling partnership agreement
Thu, 17th Sep 2020 07:00

RNS Number : 2277Z
TP Group PLC
17 September 2020

17 September 2020



TP Group plc

("TP Group", "the "Company" or the "Group")

Hydrogen fuelling partnership agreement

TP Group (AIM: TPG), the providers of mission-critical solutions for a more secure world, is pleased to announce a three-way partnership agreement with Vanguard Sustainable Transport Solutions Ltd. ("Vanguard") and Fuel Cell Systems Ltd. ("FCSL") to target hydrogen fuelling solutions in the rail industry.

The three-year, non-exclusive agreement will explore opportunities for a range of services, including on-site hydrogen generation, storage and dispensation, and fuel cell integration into rail rolling stock such as the HydroFLEX train, which has been developed by the University of Birmingham's Centre for Railway Research and Education (BCRRE) alongside rolling stock solutions provider, Porterbrook.

Vanguard is a spin-out from Birmingham University and has worked extensively on the development and integration of the HydroFLEX train. FCSL is a specialist engineering and consultancy business focused on fuel cell technology and hydrogen dispensing, which has also been part of the HydroFLEX project.

Phil Cartmell, Chief Executive Officer of TP Group, commented:

"We are very pleased to join the team working on the HydroFLEX project. Together, our three companies bring a wealth of specialist experience and technologies and are well placed to deliver innovative real-world solutions. Our joint goal is now to explore global opportunities for hydrogen-based transport solutions and to be an influential part of this rapidly growing market sector."

Well i used to follow the Grand Old Duke Of York system for my shares i have substitute the word shares for men in the following lyrics and you will get the meaning.
I had usually bought when they had already gone up to so its about right ,now i usually set targets for trimming 10% off so i at least make some profit on the way up Lol.

“The Grand Old Duke of York” Lyrics

Oh, The grand old Duke of York,
He had ten thousand shares;
He marched them up to the top of the chart,
And he marched them down again.

And when they were up, they were up,
And when they were down, they were down,
And when they were only half-way up,
They were neither up nor down

Bet you have used this system from time to time haha.

Hi wild posted this a week or two ago about the common ground we have with N4pharma ie John Chiplin chairman of both and vaccine delivery for cancer and covid one method they are researching is oral vaccines your thoughts on this.

Copied from N4P board
DanBaker

Posts: 33

Price: 8.80

No Opinion

RE: Patent newsToday 19:17
From the Directors Talk interview dated Nov 6th 2020

Q5: What other news flow can investors expect from N4 Pharma for the rest of the year?

A5: So, as we said in the RNS, we’re starting our COVID proof of concept in vivo work imminently and that’s for our un-optimised version of the Nuvec system so once we have this data, we shouldn’t take too long, we will then look to do another follow on in vivo study with optimised versions of the product. So, we’re running the optimisation work in parallel to that first study so that we can then pull all the learnings together to come up with a further proof of concept work because the continued updates of the work as we go, enables us to keep reaching out to people to say, this is how Nuvec works.

So, investors can expect a lot more news on both the COVID proof of concept work and the optimisation work and well also be updating progress on the oral programme as soon as we get it, as it goes forward.

Finally, we’ll give an update on other applications, on top of both oral and injectable vaccines, that we see and will be a priority for the development of Nuvec.

Chelsea/WTP does anyone think we will be dropped i dont more importantly neither does scancell.
Scancells own words.....
SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:

· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.

· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.

· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.

Just a reminder and they are already checking if it works on new strain so presume it already works on old strain.
Good feeling our time is now.

Only a little snippet but may be interesting.

In addition, Microsoft's president Brad Smith is giving his company's first keynote address at CES in nearly a decade, and General Motors' chief Mary Barra is set to reveal more about its driverless car plans.

Sentence copied from BBC article link for article below.

https://www.bbc.co.uk/news/technology-55582236

Good to see one of our silent major share holders Calculus now getting the word out expect major movement in the coming weeks a perfect storm is developing for Scancell share price, though in terms of health wise having asthma a little overweight and male approaching 60 not too keen on catching Covid .
Best regards everybody lets get through this and hope we can spend the money we may make knowing we helped a little known company and excellent staff beat covid and cancer and not for a headstone in our local cemetery.

If inan is right and no reason to doubt him then if they are checking if it works on the new strain does this mean they have proven it works on the old strain , and yes Ray i am a firm believer Lindy knows Avidimab will be a game changer when let loose with Covidty.
Expect big pharma knocking scancells door down form a que please.

Kashdog....Try discussing some points of interest rather than calling anybody that veers from the science look forward to your input.
Regards

Again!!! merry Christmas sushi take care see you in the new year glad you made a profit be sure to tell when you buy back in. :-)

Hasiba/wtp another one to watch in this area is TPG they have a ot of expertise in this area from nuclear subs last year they branched out into making stand alone units for hospitals for oxygen and hydrogen for service stations and running a train.

Hi Ray cant say for definite but does mention peptides on No 6 of the diagram in this article.
https://www.n4pharma.com/nuvec/
Only just come across this company just seem to be have the same interest as Scancell will look into over Christmas when i have more time although will need plenty of it too understand the science.
ATB

You forgot this one.
https://www.independent.co.uk/arts-entertainment/what-seems-be-problem-doctor-coleman-1105857.html

Copied from N4P board
DanBaker

Posts: 33

Price: 8.80

No Opinion

RE: Patent newsToday 19:17
From the Directors Talk interview dated Nov 6th 2020

Q5: What other news flow can investors expect from N4 Pharma for the rest of the year?

A5: So, as we said in the RNS, we’re starting our COVID proof of concept in vivo work imminently and that’s for our un-optimised version of the Nuvec system so once we have this data, we shouldn’t take too long, we will then look to do another follow on in vivo study with optimised versions of the product. So, we’re running the optimisation work in parallel to that first study so that we can then pull all the learnings together to come up with a further proof of concept work because the continued updates of the work as we go, enables us to keep reaching out to people to say, this is how Nuvec works.

So, investors can expect a lot more news on both the COVID proof of concept work and the optimisation work and well also be updating progress on the oral programme as soon as we get it, as it goes forward.

Finally, we’ll give an update on other applications, on top of both oral and injectable vaccines, that we see and will be a priority for the development of Nuvec.